Aura Biosciences is a clinical-stage biotechnology company pioneering virus-like drug conjugates (VDCs), a novel therapeutic platform for treating cancer by targeting and destroying tumor cells while activating anti-tumor immunity. The company's lead product candidate is designed to treat ocular melanoma, a rare and serious cancer affecting the eye. Aura's VDC technology mimics viral particles to gain entry into cancer cells, delivering potent cytotoxic payloads directly to tumors while triggering immune system recognition and attack of cancer cells. This dual mechanism approach aims to provide superior efficacy compared to traditional cancer treatments while potentially reducing side effects by specifically targeting tumor tissue. Aura Biosciences is advancing clinical trials evaluating safety, efficacy, and optimal treatment protocols for their VDC platform in ocular melanoma and exploring applications in other solid tumor types. The company collaborates with leading cancer centers and clinical investigators to advance development programs toward regulatory approval. Backed by prominent life sciences investors and biopharmaceutical partners, Aura represents innovative science addressing significant unmet medical needs in oncology through a differentiated therapeutic approach combining targeted delivery with immunotherapy mechanisms.
Search
